Mice inoculated intranasally with murine gammaherpesvirus-68 were used to evaluate the efficacy of acyclovir (ACV) in the treatment of acute and latent infections. Effectiveness was measured by infectious virus assay of the lung (site of active replication) and infectious centre assay of spleen cells (site of latency). Intraperitoneal administration of ACV at 6-h intervals starting soon after inoculation was more effective in reducing infectious virus in the lung than was treatment with 12-hourly injections commencing 3 days post-infection. Further, ACV treatment during acute infection resulted in an approximately 10-fold reduction in the number of infectious centres in the spleen as compared to placebo-treated animals. However, once latency was established, ACV treatment was not effective in reducing the number of infectious centres in the spleen. This is the first report demonstrating that ACV can be used to minimize the replication of murine gammaherpesvirus in mice at the site of primary infection, resulting in a reduction in the number of latently infected spleen lymphocytes.
References
1.
BlaskovicD.StanekovaM.SvobodovaJ., and MistrikovaJ. (1980) Isolation of five strains of herpes viruses from two species of free living rodents. Acta Virol24: 468.
2.
ColbyB.M.FurmanP.A.ShawJ.E.ElionG.B., and PaganoJ.S. (1981) Phosphorylation of acyclovir [9-(2-hydroxyethoxymethyl) guanine] in Epstein-Barr virus-infected lymphoblastoid cell lines. J Virol38: 606–611.
3.
DattaA.K.ColbyB.M.ShawJ.E., and PaganoJ.S. (1980) Acyclovir inhibition of Esptein-Barr virus replication. Proc Natl Acad Sci USA77: 5163–5166.
4.
EfstathiouS.HoY.M., and MinsonA.C. (1990a) Cloning and molecular characterization of the murine herpesvirus 68 genome. J Gen Virol71: 1355–1364.
5.
EfstathiouS.HoY.M.HallS.StylesC.J.ScottS.D., and GompelsU.A. (1990b) Murine herpesvirus 68 is genetically related to the gamma herpes viruses Epstein-Barr virus and herpesvirus saimiri. J Gen Virol71: 1365–1372.
6.
ElionG.B.FurmanP.A.FyfeJ.A.de MirandaP.BeauchampL., and SchaefferJ. (1977) Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine. Proc Natl Acad Sci USA74: 5716–5720.
FiddianA.P.KinghornG.R.GlodmeierD.ReesE.RodinR.ThinR.N.T., and de KoningG.A.J. (1983) Acyclovir and Epstein-Barr virus infection. J Antimicrob Chemother12 (suppl. B): 67–77.
9.
FieldH.J. (1982) Development of clinical resistance to acyclovir in herpes simplex virus infected mice receiving oral therapy. Antimicrob Chemother21: 744–752.
10.
FieldH.J., and DarbyG. (1980) Pathogenicity in mice of strains of herpes simplex virus which are resistant to acyclovir in vitro and in vivo. Antimicrob Chemother17: 209–216.
11.
FieldH.J., and De ClercqE. (1981) Effects of oral treatment with acyclovir and bromovinyl deoxyuridine on the establishment and maintenance of latent herpes simplex virus infection in mice. J Gen Virol56: 259–265.
12.
FieldH.J.BellS.E.ElionG.B.NashA.A., and WildyP. (1979) Effect of acycloguanosine treatment on acute and latent herpes simplex infections in mice. Antimicrob Chemother15: 554–561.
13.
FieldH.J.AndersonJ.R., and EfstathiouS. (1984) A quantitative study of the effects of nucleoside analogues on established herpes encephalitis in mice. J Gen Virol65: 707–719.
14.
HonessR.W.O'HareP.YoungD. (1982) Comparison of thymidine kinase activities induced in cells productively infected with herpesvirus saimiri and herpes simplex virus. J Gen Virol58: 237–249.
MillerW.H., and MillerR.L. (1980) Phosphorylation of acyclovir monophosphate by GMP kinase. J Biol Chem255: 7204–7207.
17.
MillerW.H., and MillerR.L. (1982) Phosphorylation of acyclovir diphosphate by cellular enzymes. Biochem Pharmacol31: 3879–3884.
18.
MillerG.NiedermanJ.C., and AndewsL. (1973) Prolonged oropharyngeal excretion of EB virus following infectious mononucleosis. N Eng J Med288: 229–232.
19.
MindelA., and SutherlandS. (1983) Acyclovir and Epstein-Barr virus infection. J Antimicrob Chemother12 (suppl. B): 51–59.
20.
PaganoJ.S.SixbeyJ.W., and LinJ.-C. (1983) Acyclovir and Epstein-Barr virus infection. J Antimicrob Chemother12 (suppl. B): 113–121.
21.
PirschJ.D.StrattaR.J.SollingerH.W.HafezG.R.D'AllessandroA.M.KalayogluM., and BeizerF.O. (1989) Treatment of severe Epstein-Barr virus induced lymphoproliferative syndrome with ganciclovir: two cases after solid organ transplantation. Am J Med86(2): 241–244.
22.
ResnickL.HershtJ.AblashiD.AthertonS.FrankB.RosenL., and HorwitzS.N. (1988) Regression of “oral hairy leucoplakia” after orally administered acyclovir therapy. JAMA259(3): 384–388.
23.
SchaefferH.J.BeauchampL.de MirandaP., and ElionG.B. (1978) 9-(2-Hydroxyethoxymethyl) guanine activity against viruses of the herpes group. Nature272: 583–585.
24.
Sunil-ChandraN.P.EfstathiouS.ArnoJ., and NashA.A. (1992a) Virological and pathological features of mice ifnected with murine gammaherpesvirus 68. J Gen Virol73: 2347–2356.
25.
Sunil-ChandraN.P.EfstathiouS., and NashA.A. (1992b) Murine gammaherpesvirus-68 establishes a latent infection in mouse B lymphocytes in vivo. J Gen Virol73: 3275–3279.
26.
Sunil-ChandraN.P.EfstathiouS., and NashA.A. (1993) Interactions of murine gammaherpesvirus 68 with B and T cell lines. Virol193: 825–833.
27.
YaoQ.Y.OganP.RoweM.WoodM., and RickinsonA.B. (1989a) The Epstein-Barr virus: host balance in acute infectious mononucleosis patients receiving acyclovir antiviral therapy. Int J Cancer43: 61–66.
28.
YaoQ.Y.OganP.RoweM.WoodM., and RickinsonA.B. (1989b) Epstein-Barr virus-infected B cells persist in the circulation of acyclovir treated virus carriers. Int J Cancer43: 67–71.
29.
ZutterM.MartinP.J., and SaleG.E. (1988) Epstein-Barr virus lymphoproliferation after bone marrow transplantation. Stood72: 520–529.
